Spruce Biosciences
SPRB
32 hedge funds and large institutions have $65.6M invested in Spruce Biosciences in 2025 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
1,150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 2
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
256% more funds holding
Funds holding: 9 → 32 (+23)
161% more capital invested
Capital invested by funds: $25.1M → $65.6M (+$40.5M)
27.39% more ownership
Funds ownership: 0% → 27.39% (+27%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$11.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$7.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.32M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$6.21M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$5.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
-$306M |
| 2 |
CCC
Cable Car Capital
San Francisco,
California
|
-$239K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$931 |
SPRB Hedge Fund Activity: Q4 2025 in Review
32 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q4 2025, worth a combined $65.6M — up 161% from $25.1M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SPRB positions and 2 closed out — a net gain of 23 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $11.6M. The largest seller was Carlyle Group, cutting an estimated $306M.
- 32 institutional investors held Spruce Biosciences (SPRB) as of Q4 2025, up from 9 in Q3 2025.
- Funds reported $65.6M of Spruce Biosciences stock for Q4 2025, up 161% quarter-over-quarter.
- 25 funds opened new Spruce Biosciences positions in Q4 2025 and 2 closed out, a net change of +23 holders.
- The largest Spruce Biosciences buyer in Q4 2025 was Ikarian Capital, an estimated $11.6M added.
- The largest Spruce Biosciences seller in Q4 2025 was Carlyle Group, an estimated $306M sold.
Based on aggregated 13F filings for Q4 2025.